OraSure Technologies (OSUR) has just posted another loss making quarter, with Q4 FY 2025 revenue of US$26.8 million and a basic EPS loss of US$0.27, alongside trailing 12 month revenue of US$115.0 million and a basic EPS loss of US$0.94. The company has seen quarterly revenue move from US$39.9 million in Q3 FY 2024 to US$37.4 million in Q4 FY 2024 and then into the US$26.8 million to US$31.2 million range through FY 2025. EPS shifted from a loss of US$0.06 in Q3 FY 2024 to losses between US$0.19 and US$0.27 per quarter in FY 2025, so the latest print keeps the focus firmly on how quickly margins can stabilize from here.

With the headline numbers on the table, the next step is to line these results up against the most common narratives around OraSure to see which views are supported by the data and which might need a rethink.

Losses Deepen On A Smaller Revenue Base

• Across FY 2025, revenue moved from US$37.4 million in Q4 FY 2024 to a range of US$26.8 million to US$31.2 million per quarter, while quarterly net losses widened from US$10.8 million in Q4 FY 2024 to between US$13.7 million and US$19.7 million in FY 2025.
• Bears highlight that earnings have declined about 9.5% per year over five years, and the recent pattern of losses, such as US$19.3 million in Q4 FY 2025 and US$68.7 million over the last twelve months, lines up with that concern that the business is still running at a loss even on a smaller revenue base.

Skeptics warn that this combination of shrinking trailing twelve month revenue, from US$185.8 million in Q4 FY 2024 to US$115.0 million in Q4 FY 2025, and deeper losses keeps the focus on whether the core business can support its cost structure over time. 🐻 OraSure Technologies Bear Case

Trailing Twelve Month Trend Stays Firmly In The Red

• On a trailing twelve month view, OraSure swung from a profit of US$11.4 million in Q3 FY 2024 to a loss of US$68.7 million by Q4 FY 2025, with basic EPS moving from a gain of US$0.15 to a loss of US$0.94 over the same window.
• Consensus narrative talks about long term margin improvement potential, but the move in trailing EPS from a loss of US$0.26 at Q4 FY 2024 to a loss of US$0.94 by Q4 FY 2025 underlines how far actual profitability is from the analysts’ assumption that margins could eventually reach industry like levels.

Valuation Looks Cheap On Sales While Growth Stays Modest

• OraSure trades on a P/S ratio of 1.9x, which is below the 2.9x average for the US Medical Equipment industry and below the 2.6x peer average. At the same time, revenue growth is forecast at 3.5% per year compared with 10.4% for the broader US market.
• Bullish investors point to the lower P/S multiple as support for upside potential, yet the current loss position, with trailing twelve month net losses of US$68.7 million and no profitability in the last six reported quarters, pushes back on the idea that the market is simply overlooking a clean growth story.

With the share price around US$3.08 against an analyst price target of US$6.00, the gap between valuation on sales and the ongoing losses is exactly what bulls and bears are debating. 🐂 OraSure Technologies Bull Case

Next Steps

To see how these results tie into long-term growth, risks, and valuation, check out the full range of community narratives for OraSure Technologies on Simply Wall St. Add the company to your watchlist or portfolio so you'll be alerted when the story evolves.

If this all sounds mixed, it is the kind of setup where looking at the details yourself really matters, especially while sentiment is still forming. Before you make up your mind on OraSure, it is worth checking the 1 important warning sign that our analysis has picked up and seeing how they line up with your own expectations.

See What Else Is Out There

OraSure is contending with shrinking revenue, deeper losses and no recent profitability, so the core business is still working hard just to stand still.

If those issues make you want more resilient ideas, check out our 79 resilient stocks with low risk scores today and quickly shortlist companies where financial risk is already tightly controlled.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.